Sequenom
1994
FOUNDED
M&A
STATUS
401-500
EMPLOYEES
M&A
LATEST DEAL TYPE
$371M
LATEST DEAL AMOUNT
Description
Provider of genetic analysis products and diagnostic tests for non-invasive prenatal genetic disorders. The company provides nucleic acid analysis platform that measures genetic target material and variations.
Website
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Monitoring Equipment
Parent Company
Primary Office
- 3595 John Hopkins Court
- San Diego, CA 92121
- United States
+1 (858) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Sequenom’s full profile, request a free trial.
Sequenom Valuation and Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 18. Merger/Acquisition | 07-Sep-2016 | $371M | 00000 | 00000 | Completed | Profitable |
| 17. Debt Refinancing | 18-Jun-2015 | 0000 | 00000 | Completed | Profitable | |
| 16. Debt - General | 20-Sep-2012 | 00000 | 00000 | Completed | Profitable | |
| 15. 2PO | 25-Jan-2012 | 0000 | 00000 | Completed | Profitable | |
| 14. Debt - General | 02-Jun-2011 | 0000 | 00000 | Completed | Profitable | |
| 13. PIPE | 21-May-2010 | 000.00 | 00000 | Completed | Profitable | |
| 12. PIPE | 23-Dec-2009 | 00.000 | 00000 | Completed | Profitable | |
| 11. PIPE | 09-Mar-2009 | 00.000 | 00000 | Completed | Profitable | |
| 10. PIPE | 19-Nov-2008 | $3.6M | $249M | Completed | Profitable | |
| 9. Secondary Transaction - Open Market | 01-Aug-2008 | $245M | Completed | Profitable |
Sequenom Acquisitions (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000000 | 27-Jan-2009 | 000000000000000000 | Biotechnology | 00000 000000 00.0 | |
| Sequenom Center for Molecular Medicine | 17-Nov-2008 | Merger/Acquisition | 000 | Laboratory Services (Healthcare) |
Sequenom Former Investors (18)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Board Seat |
Contact Info |
|---|---|---|---|---|---|---|
| Comvest Partners | PE/Buyout | Minority | 000 0000 | 000000 0 | ||
| Delaware Crossing Investor Group | Angel Group | Minority | 000 0000 | 000000 0 | ||
| Fort Mason Capital | PE/Buyout | Minority | 000 0000 | 000000 0 | ||
| Global Life Science Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | ||
| Haspa BGM | PE/Buyout | Majority | 000 0000 | 000000 0 |
Sequenom Executive Team (16)
9 Former Executives
You’re viewing 5 of 16 executives. Get the full list »Sequenom Board Members (10)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| Catherine Mackey Ph.D | Self | Board Member | 000 0000 | |
| Charles Slacik | Sequenom | Director | 000 0000 | |
| David Pendarvis | Sequenom | Director | 000 0000 | |
| Dirk van den Boom Ph.D | Sequenom | President, Chief Executive Officer, Board Member, Chief Scientific & Chief Strategy Officer | 000 0000 | |
| John Fazio | Self | Director | 000 0000 |
1 Former Board Member
You’re viewing 5 of 10 board members. Get the full list »